Darunavir/ritonavir and rilpivirine in therapy-naïve patients.

Registry ID

EUCTR2012-002663-10

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

St Stephen's AIDS Trust

Start date

2012-10-16

Completion date

2015-03-16

Last update

2026-08-16

Conditions

• HIV-1

Summary

To see how well the study regime suppresses the HIV-1 virus after 48 weeks of therapy.

Locations

• , , UK

Related clinical trials

• Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
• Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
• CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
• Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
• Viral Infection of HSPC Impacts Hematopoiesis

View on source registry